Skip to main content
Caplight Logo









iOmx Therapeutics

iOmx Therapeutics

Private
GermanyHealthcare & Life Scienceshttps://www.iomx.com/

Last Round

Series B

Oct 5, 2021

Total Funding Raised

$120.2M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

iOmx Therapeutics is a biopharmaceutical company that develops cancer immunotherapies by targeting novel immune checkpoints on tumor cells.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

cancer immunotherapyimmune checkpointimmuno-oncologydrug discoveryoncologybiotechnologybiopharmatarget discoveryprecision medicinetumor resistanceCRISPR screeningantibody therapydrug pipelineclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

iOmx Therapeutics Comparables

Compare iOmx Therapeutics with similar companies based on industry and business-model similarity.

iOmx Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CatalYm
83%
Ipsen
81%
ImmunOs Therapeutics
77%

iOmx Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BOct 5, 2021
Series ASep 22, 2016

Key People

Founding team and executive leadership

Apollon Papadimitriou

CEO

Executive Team

Florian Schmid

CFO

Executive Team

iOmx Therapeutics Investors

Notable investors and investment history

iOmx Therapeutics investors
InvestorRounds
MPM CapitalSeries A
MIG CapitalSeries B
M VenturesSeries A, Series B
MPM BioImpactSeries A
Sofinnova PartnersSeries B, Series A
Wellington PartnersSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 22, 2026

    Monthly visitors grew 47% MoM.

  • Sep 22, 2016

    $45M round led by MPM BioImpact, MPM Capital, and Sofinnova Partners.

iOmx Therapeutics Filings

Explore SEC and related filing metadata, where available.

iOmx Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about iOmx Therapeutics's valuation, stock price, and market status.

Is iOmx Therapeutics a public or private company?

iOmx Therapeutics is a private company.

What is the current stock price of iOmx Therapeutics?

iOmx Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is iOmx Therapeutics worth (valuation)?

Valuation information for iOmx Therapeutics is not publicly available.

Can I buy iOmx Therapeutics stock?

iOmx Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was iOmx Therapeutics's last funding round?

iOmx Therapeutics's most recent funding round was Series B on October 5, 2021.

Who are the main investors in iOmx Therapeutics?

Key investors in iOmx Therapeutics include MPM Capital, MIG Capital, Sofinnova Partners.

Will iOmx Therapeutics IPO soon?

No public IPO plans have been announced for iOmx Therapeutics.

How can I track iOmx Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor iOmx Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersGermany
Employee Range43
Year Founded2016
Last FundingOct 5, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?